Breast Cancer
Clinical Trials
1) Up to 3 lines of post-adjuvant or neoadjuvant therapy for TNBC/AYALA: AL-TNBC-01: A Phase 2, Multicenter, Open-label study of AL101 Monotherapy in Patients with Notch Activated Recurrent or Metastatic Triple Negative Breast Cancer
2) First line for locally advanced/ metastatic ER+ HER2 Neg/ BO41843: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of GD9545 Combined with Palbociclib Compared with Letrozole Combined with Palbociclib in Patients with ER+, HER2 Neg Locally Advanced or Metastatic Breast Cancer
3) First and Second line of therapy (dependent upon monotherapy or combination therapy/Zeno 001: A Phase 1/2 Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of ZN-c5 Alone and in Combination with Palbociclib in Subjects with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer.
4) First line advanced/metastatic ER+ HER2 Neg ZENO 003 (ON HOLD): A Phase 1B Study of ZN-c5 in Combination with Abemaciclib in Patients with Estrogen-Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Advanced Breast Cancer
5) WO42633: A Phase 3, Randomized, Double Blind, Placebo Controlled Clinical Trail To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab OR Placebo And Trastuzumab Emtansine For HER2-Postive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy.
6) eMonoarch I3Y-MC-JPCW USO#20364: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib plus Standard Adjuvant Endocrine Therapy in patients with High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2 Targeted Therapy
Send UsA Message
The Importance of Subspecialization in Oncology: Our Commitment at Charleston Oncology
The Importance of Subspecialization in Oncology: Our Commitment at Charleston OncologyAt Charleston Oncology, we know that a cancer diagnosis can be overwhelming. For most patients, the search for the right doctor quickly becomes one of the most important steps on...
Lung Cancer in Non-Smokers: What You Should Know
Lung Cancer in Non-Smokers: What You Should KnowAt Charleston Oncology, we understand that lung cancer is often linked to smoking, but it’s important to remember that lung cancer can affect anyone, even those who have never smoked. As part of Lung Cancer Awareness...
Why Early Detection Matters: Breast Cancer Screening Guidelines By Age
Why Early Detection Matters: Breast Cancer Screening Guidelines By AgeBreast cancer is the most common cancer diagnosed in women, but it is also one of the most treatable when found early. Early detection is the single most powerful tool we have in the fight against...
Proactive Health: Prostate and Blood Cancer Awareness
Proactive Health: Prostate and Blood Cancer AwarenessTaking charge of your health means being informed and proactive, especially when it comes to cancer prevention and early detection. This September, as we observe both Prostate Cancer Awareness Month and Blood Cancer...
The Patients’ Unique Needs
From diagnosis to treatment and follow-ups, Charleston Oncology, as a part of the Department of Bon Secours St. Francis’ leading multidisciplinary cancer care team, plays a vital role in guiding patients through their breast cancer journey.
Landing on Your Feet: Celebrating Life After Cancer
From diagnosis to treatment and follow-ups, Charleston Oncology, as a part of the Department of Bon Secours St. Francis’ leading multidisciplinary cancer care team, plays a vital role in guiding patients through their breast cancer journey.
